PT-141 10mg

PT-141 (Bremelanotide) 10mg — The Melanocortin Peptide Redefining Sexual Health & Libido Research

PT-141, scientifically designated Bremelanotide, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (α-MSH) that has emerged as one of the most uniquely positioned compounds in contemporary peptide research. Unlike the vast majority of agents studied for sexual health applications — which primarily target vascular mechanisms such as phosphodiesterase inhibition — PT-141 operates through a fundamentally different and neurologically mediated pathway, acting directly on the central nervous system to activate melanocortin receptors implicated in sexual arousal, motivation, and desire.

Available in a research-grade 10mg lyophilized vial, PT-141 Bremelanotide represents a milestone compound for investigators exploring the neurobiology of sexual function, melanocortin receptor pharmacology, and the central regulation of desire and arousal. Its distinctive mechanism, favorable selectivity profile, and growing body of clinical literature make it one of the most compelling peptides available for advanced research protocols today.

What Is PT-141? Origin, Structure & Pharmacological Profile

PT-141 was first developed as a sunless tanning agent derived from Melanotan II (MT-II), a broader-spectrum melanocortin agonist. During early clinical trials of MT-II, researchers observed a striking and unexpected side effect: spontaneous sexual arousal in both male and female study participants. This serendipitous discovery redirected scientific attention toward isolating the mechanism and refining the compound to enhance its sexual function activity while minimizing other melanocortin-mediated effects.

The result was Bremelanotide — a cyclic lactam analogue engineered for improved metabolic stability and receptor specificity. Unlike MT-II, PT-141 does not significantly affect skin pigmentation at research doses, making it a cleaner pharmacological tool for isolating melanocortin receptor-mediated sexual function pathways. In 2019, the FDA approved a subcutaneous injectable formulation of Bremelanotide (Vyleesi) for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women — a landmark development that validated decades of research interest in the compound.

Molecular Identity & Chemical Properties

PT-141 is a cyclic heptapeptide with the amino acid sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. Its cyclic structure confers exceptional resistance to enzymatic degradation relative to linear peptides, resulting in a more extended half-life and sustained receptor engagement. The molecular formula is C50H68N14O10, with a molecular weight of approximately 1025.18 g/mol. In lyophilized form, PT-141 is a stable white to off-white powder that reconstitutes readily in bacteriostatic water or sterile saline.

Melanocortin Receptor Selectivity of PT-141

The melanocortin system comprises five receptor subtypes (MC1R through MC5R) distributed across the brain, skin, adrenal glands, and peripheral tissues. PT-141 demonstrates primary agonist activity at MC3R and MC4R — two receptor subtypes expressed in the hypothalamus and limbic system that play established roles in regulating sexual behavior, appetite, and autonomic function. It is the activation of MC4R in particular — within the paraventricular nucleus of the hypothalamus — that is believed to underlie PT-141’s pro-erectile and pro-arousal effects. This centrally mediated action distinguishes PT-141 sharply from PDE5 inhibitors such as sildenafil, which act peripherally on vascular smooth muscle.

Research Applications & Observed Effects of PT-141 Bremelanotide

1. Sexual Arousal & Desire Pathway Research

The primary research application of PT-141 centers on the central neurological pathways governing sexual arousal and desire. Studies in both animal models and human clinical trials have demonstrated that PT-141 reliably increases sexual motivation, genital arousal, and the subjective experience of desire through its action on hypothalamic MC3R and MC4R receptors. This central mechanism makes PT-141 particularly relevant in research contexts involving neurogenic or psychogenic sexual dysfunction, where peripheral vascular treatments have limited efficacy.

2. Male Sexual Function & Erectile Response Studies

PT-141 has been extensively studied in male subjects for its capacity to facilitate erectile responses through a CNS-dependent mechanism. Clinical trials demonstrated statistically significant improvements in erectile function scores compared to placebo, with effects observed regardless of baseline vascular health status. This finding is particularly significant because it suggests PT-141 may be effective in research models where nitric oxide-mediated erectile pathways are compromised — offering a complementary or alternative mechanistic approach for investigators studying male sexual dysfunction.

3. Female Sexual Desire & HSDD Research

The FDA approval of subcutaneous Bremelanotide for hypoactive sexual desire disorder (HSDD) in premenopausal women is grounded in robust Phase II and Phase III clinical data. Research consistently demonstrated that PT-141 increased the number of satisfying sexual events, reduced personal distress associated with low desire, and improved Female Sexual Function Index (FSFI) scores. For researchers

studying female sexual dysfunction, PT-141 represents the gold-standard centrally acting reference compound, enabling direct investigation of melanocortin-mediated desire mechanisms in a well-characterized research population.

4. Hypothalamic Neuroscience & Melanocortin System Research

Beyond its direct sexual function applications, PT-141 is a valuable pharmacological probe for mapping melanocortin receptor function within hypothalamic circuits. Researchers have employed PT-141 to study MC4R’s role in energy homeostasis, stress response modulation, inflammation, and autonomic nervous system regulation. Its selectivity for MC3R and MC4R, combined with its CNS penetration and predictable pharmacokinetics, makes it a preferred tool for dissecting melanocortin receptor biology in neuroscience research settings.

Product Specifications: PT-141 Bremelanotide 10mg Vial

Technical & Analytical Specifications

• Peptide name: PT-141 (Bremelanotide)
• Sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
• Molecular formula: C50H68N14O10
• Molecular weight: 1025.18 g/mol
• CAS number: 189691-06-3
• Vial size: 10mg lyophilized powder
• Purity: ≥99% (verified by HPLC and mass spectrometry)
• Appearance: White to off-white lyophilized powder
• Reconstitution: Bacteriostatic water or sterile saline
• Storage: 2–8°C refrigerated; stable at –20°C long-term
• Shelf life: 24 months lyophilized (sealed vial, refrigerated)

Quality Assurance & Documentation

Each 10mg vial of PT-141 is produced under GMP-compliant manufacturing conditions and independently tested by certified third-party analytical laboratories. A full Certificate of Analysis (CoA) confirming peptide identity by mass spectrometry, sequence verification, HPLC purity, and sterility testing is available for every production batch. Our commitment to analytical rigor ensures researchers receive only the highest-confidence material for their protocols.

Research Use Classification

PT-141 Bremelanotide 10mg is supplied exclusively for in vitro laboratory research and preclinical investigation. This product is not intended for human self-administration, is not a licensed medicinal product in this presentation, and must be handled in strict accordance with all applicable institutional and jurisdictional regulations governing research peptides and investigational compounds.

Why Source PT-141 From Our Research Peptide Catalogue?

Peptide quality is the single most important variable in research reproducibility, and our PT-141 Bremelanotide is held to the highest analytical standards in the industry. Synthesized via solid-phase peptide synthesis (SPPS) using Fmoc chemistry and purified by reverse-phase HPLC to achieve greater than 99% purity, our PT-141 delivers the consistency and confidence that serious research demands.

Our 10mg vial format is optimally sized for multi-dose research protocols, providing researchers with sufficient material for thorough dose-response investigations without unnecessary excess. Combined with reliable logistics, full batch documentation, and dedicated research support, we are the trusted source for PT-141 Bremelanotide and a comprehensive range of premium research peptides.